Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...
The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, ...
LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms ...
The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...
The world's first IVF baby, Louise Brown born in England in 1978, was conceived from a naturally developing follicle in her mother's ovary. However, as other groups around the world would quickly ...
GENEVA, Switzerland December 17, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback